Literature DB >> 29901415

Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.

Angie N Pinto1, Pat Grey1, Ansari Shaik1, David A Cooper1, Anthony D Kelleher1, Kathy Petoumenos1.   

Abstract

The aim of this study was to understand factors associated with increased mortality in a cohort of primary HIV infection (PHI) in New South Wales (NSW) over three decades. Six hundred and two patients with PHI were enrolled from 1984 to 2009. Probabilistic data linkage was performed to NSW Registry of births deaths and marriages and Australian Bureau of Statistics mortality database. Mortality was measured by crude death rate. Pre highly active antiretroviral therapy (pre-HAART) era was defined as before January 1, 1997. A Cox proportional hazard model was used to identify factors associated with death. One hundred and thirty-eight deaths occurred during 6,223 person years (PY) follow-up. Overall crude death rate was 2.2 per 100 PY (95% confidence interval [CI], 1.9-2.6), 3.6 (95% CI, 3.1-4.3)in pre-HAART era and 0.20 (95% CI, 0.08-0.47) in post-HAART era. AIDS was the most frequent cause of death (52%, 72/138), all occurring in the pre-HAART era. Of non-AIDS deaths, the leading known cause was non-AIDS cancer 8% (11/138) followed by suicide 4% (6/138). On multivariate analysis, estimated date of infection in pre-HAART era and time to commencement of ART greater than 1 year post diagnosis were more likely to be associated with death (p < .05). Mortality in PHI has decreased significantly in the post-HAART era. Non-AIDS deaths due to malignancy and suicide are emerging as leading causes in this population in the post-HAART era. Time to starting ART greater than 1 year was associated with increased mortality.

Entities:  

Keywords:  HIV; mortality; seroconversion

Mesh:

Substances:

Year:  2018        PMID: 29901415      PMCID: PMC6238611          DOI: 10.1089/AID.2017.0284

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  27 in total

1.  A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Authors:  Frederick M Hecht; Lei Wang; Ann Collier; Susan Little; Martin Markowitz; Joseph Margolick; J Michael Kilby; Eric Daar; Brian Conway; Sarah Holte
Journal:  J Infect Dis       Date:  2006-08-15       Impact factor: 5.226

2.  Risk factors and causes of death in the Australian HIV Observational Database.

Authors:  Kathy Petoumenos; Matthew G Law
Journal:  Sex Health       Date:  2006-05       Impact factor: 2.706

3.  Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.

Authors:  S Emery; C Workman; R L Puls; M Bloch; D Baker; N Bodsworth; J Anderson; S M Crowe; M A H French; J Hoy; A Aichelburg; L D Ward; D B Boyle; M G Law; A D Kelleher; D A Cooper
Journal:  Hum Vaccin       Date:  2005-11-12

4.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Authors:  Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  Lancet       Date:  2014-07-19       Impact factor: 79.321

5.  Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship.

Authors:  P Vanhems; J Lambert; D A Cooper; L Perrin; A Carr; B Hirschel; J Vizzard; S Kinloch-de Loës; R Allard
Journal:  Clin Infect Dis       Date:  1998-02       Impact factor: 9.079

6.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

7.  Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.

Authors:  Sara Croxford; Aileen Kitching; Sarika Desai; Meaghan Kall; Michael Edelstein; Andrew Skingsley; Fiona Burns; Andrew Copas; Alison E Brown; Ann K Sullivan; Valerie Delpech
Journal:  Lancet Public Health       Date:  2016-12-15

8.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

9.  High viral fitness during acute HIV-1 infection.

Authors:  Alicia Arnott; Darren Jardine; Kim Wilson; Paul R Gorry; Kate Merlin; Patricia Grey; Matthew G Law; Elizabeth M Dax; Anthony D Kelleher; Don E Smith; Dale A McPhee
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

10.  Short-course antiretroviral therapy in primary HIV infection.

Authors:  Sarah Fidler; Kholoud Porter; Fiona Ewings; John Frater; Gita Ramjee; David Cooper; Helen Rees; Martin Fisher; Mauro Schechter; Pontiano Kaleebu; Giuseppe Tambussi; Sabine Kinloch; Jose M Miro; Anthony Kelleher; Myra McClure; Steve Kaye; Michelle Gabriel; Rodney Phillips; Jonathan Weber; Abdel Babiker
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

View more
  3 in total

Review 1.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622

Review 2.  How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy.

Authors:  Anthony Jaworowski; Anna C Hearps; Thomas A Angelovich; Jennifer F Hoy
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

3.  Pyrimidine 2,4-Diones in the Design of New HIV RT Inhibitors.

Authors:  Roberto Romeo; Daniela Iannazzo; Lucia Veltri; Bartolo Gabriele; Beatrice Macchi; Caterina Frezza; Francesca Marino-Merlo; Salvatore V Giofrè
Journal:  Molecules       Date:  2019-05-02       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.